Maravai LifeSciences Holdings, Inc. MRVI Noncash Or Part Noncash Acquisition Payables Assumed1

Noncash Or Part Noncash Acquisition Payables Assumed1 at other companies

Personalis, Inc.PSNL

$3.04M+1,066%

Revenue$65.8M+40.5%

Gross profit$33.7M+336%

Operating income-$2.2M+95.6%

Net income-$3.7M+87.5%

EPS (diluted)-$0.02+90.5%

Cash & equivalents$165.9M-41.8%

Total debt$270.9M-17.1%

Total equity$211.6M-29.6%

Total assets$713.2M-25.7%

Operating cash flow$8.7M+192%

CapEx$4.4M-1.4%

Free cash flow$4.2M+130%

Market cap$902.74M+204%

Enterprise value$1.01B+198%

P/S4.4×+3.2×

Gross margin29.3%-8.0pp

Operating margin-82.2%-16.6pp

Net margin-51.1%-9.9pp

FCF margin-25.7%—

Return on equity-40.8%-4.0pp

Debt / equity1.3×+0.2×

Current ratio5.9×-0.1×

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Maravai LifeSciences Holdings, Inc.'s noncash or part noncash acquisition payables assumed1?: Maravai LifeSciences Holdings, Inc. (MRVI) reported noncash or part noncash acquisition payables assumed1 of $0 in Q1 2026.
How has Maravai LifeSciences Holdings, Inc.'s noncash or part noncash acquisition payables assumed1 changed year-over-year?: Maravai LifeSciences Holdings, Inc.'s noncash or part noncash acquisition payables assumed1 decreased by 100.0% year-over-year, from $2.33M to $0.